Correction (DOI:10.1016/j.jvs.2008.02.062);Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions

Journal of Vascular Surgery

Volumn 48, Issue 1, 2008, Pages 144-149

  Iida, Osamu ^a   Nanto, Shinsuke ^a   Uematsu, Masaaki ^a   Morozumi, Takakazu ^a   Kitakaze, Masafumi ^b   Nagata, Seiki ^a  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; CILOSTAZOL; TICLOPIDINE;

AGED; ARTICLE; BALLOON DILATATION; BLOOD FLOW VELOCITY; BRAIN HEMORRHAGE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG FATALITY; DRUG WITHDRAWAL; ENDOVASCULAR THERAPY; FEMALE; FEMOROPOPLITEAL LESION; FOLLOW UP; GASTRIC ULCER BLEEDING; HEADACHE; HEART PALPITATION; HUMAN; LEG EDEMA; LEG REVASCULARIZATION; LIMB AMPUTATION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONSURGICAL INVASIVE THERAPY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYSTOLE; THROMBOSIS; VASCULAR LESION; VASCULAR PATENCY;

EID: 45549101498     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2008.10.018     Document Type: Erratum

References (29)

1. Anderson P.L., Gelijns A., Moskowitz A., Arons R., Gupta L., Weinberg A., et al. Understanding trends in inpatient surgical volume: vascular interventions, 1980-2000. J Vasc Surg 39 (2004) 1200-1208
2. Dormandy J.A., and Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Ticlopidine group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31 (2000) S1-S296
3. Goshima K.R., Mills J.L., and Hughes J.D. A new look at outcomes after infrainguinal bypass surgery: traditional reporting standards systematically underestimate the expenditure of effort required to attain limb salvage. J Vasc Surg 39 (2004) 330-335
4. Jahnke T., Voshage G., Muller-Hulsbeck S., Grimm J., Heller M., and Brossmann J. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 13 (2002) 257-266
5. Mewissen M.W. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech Vasc Interv Radiol 7 (2004) 2-5
6. Sabeti S., Schillinger M., Amighi J., Sherif C., Mlekusch W., Ahmadi R., et al. Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology 232 (2004) 516-521
7. Vogel T.R., Shindelman L.E., Nackman G.B., and Graham A.M. Efficacious use of nitinol stents in the femoral and popliteal arteries. J Vasc Surg 38 (2003) 1178-1184
8. Schillinger M., Sabeti S., Dick P., Amighi J., Mlekusch W., Schlager O., et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 115 (2007) 2745-2749
9. Schillinger M., Sabeti S., Loewe C., Dick P., Amighi J., Mlekusch W., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354 (2006) 1879-1888
10. Minar E., Pokrajac B., Ahmadi R., Maca T., Seitz W., Stümpflen A., et al. Brachytherapy for prophylaxis of restenosis after long-segment femoropopliteal angioplasty: pilot study. Radiology 208 (1998) 173-179
11. Wyttenbach R., Gallino A., Alerci M., Mahler F., Cozzi L., Di Valentino M., et al. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery by noninvasive magnetic resonance imaging. Circulation 110 (2004) 1156-1161
12. Krueger K., Zaehringer M., Bendel M., Stuetzer H., Strohe D., Nolte M., et al. De novo femoropopliteal stenoses: endovascular gamma irradiation following angioplasty-angiographic and clinical follow-up in a prospective randomized controlled trial. Radiology 231 (2004) 546-554
13. Duda S.H., Pusich B., Richter G., Landwehr P., Oliva V.L., Tielbeek A., et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 106 (2002) 1505-1509
14. Duda S.H., Bosiers M., Lammer J., Scheinert D., Zeller T., Oliva V., et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 13 (2006) 701-710
15. Duda S.H., Bosiers M., Lammer J., Scheinert D., Zeller T., Tielbeek A., et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 16 (2005) 331-338
16. Iida O., Nanto S., Uematsu M., Morozumi T., Kotani J., Awata M., et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 69 (2005) 1256-1259
17. Ranke C., Creutzig A., and Alexander K. Duplex scanning of peripheral arteries: correlation of the peak velocity ratio with angiographic diameter reduction. Ultrasound Med Biol 18 (1992) 433-440
18. Laird J.R. Limitations of percutaneous transluminal angioplasty and stenting for the treatment of disease of the superficial femoral and popliteal arteries. J Endovasc Ther 13 (2006) II30-II40
19. Schlager O., Dick P., Sabeti S., Amighi J., Mlekusch W., Minar E., et al. Long-segment SFA stenting-the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther 12 (2005) 676-684
20. Adam D.J., and Bradbury A.W. TASC II document on the management of peripheral arterial disease. Eur J Vasc Endovasc Surg 33 (2007) 1-2
21. Grimm J., Müller-Hülsbeck S., Jahnke T., Hilbert C., Brossmann J., and Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol 12 (2001) 935-942
22. Douglas J.S., Holmes D.R., Kereiakes D.J., Grines C.L., Block E., Ghazzal Z.M., et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112 (2005) 2826-2832
23. Dawson D.L., Cutler B.S., Meissner M.H., and Strandness D.E. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (1998) 678-686
24. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease. Circulation 113 (2006) e463-e654
25. Sudo T., Tachibana K., Toga K., Tochizawa S., Inoue Y., Kimura Y., et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59 (2000) 347-356
26. Kimura Y., Tani T., Kanbe T., and Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985) 1144-1149
27. Kawamura K., Watanabe K., and Kimura Y. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. Arzneimittelforschung 35 (1985) 1149-1154
28. Shintani S., Watanabe K., Kawamura K., Mori T., Tani T., Toba Y., et al. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs. Arzneimittelforschung 35 (1985) 1163-1172
29. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., et al. Effect of cilostazol, cyclic AMP phosophodiesteraze in-hibitot,on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Phamacol 20 (1992) 900-906